General AML

Prof. Arnon Nagler | EBMT 2018 | Prospects of immune checkpoint inhibitors for prevention of SCT relapse in AML


Prof. Arnon Nagler from Tel Aviv University, Tel Aviv, IL, discusses at 44th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting the use of immune checkpoint inhibitors for the prevention of post-transplantation relapse in patients with acute myeloid leukemia. Leukemia cells express PD-L1, which they use to evade the immune system and cause relapse. Using checkpoint inhibitors such as nivolumab, a PD-1 inhibitor, might be a strategy to prevent post-transplant relapse in AML patients. 

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF